Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage small-cell lung cancer: A randomized, controlled, open-label, single-center phase ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Solar accounted for more than 72% of US electrical generating capacity added in 2025, with another 16% from wind, according to belatedly released data from the Federal Energy Regulatory Commission ...

Star Wars producer Kathleen Kennedy was one of the few skeptics at the Runway AI Summit, where AI was compared to fire and the printing press just a week after Sora’s death. As Kennedy told an ...

OpenAI's nascent ads business has surpassed $100 million in annual recurring revenue less than two months after launching its pilot in the U.S., according to a spokesperson. The company said in ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The Federal Reserve's pause on rate cuts means investors can still grab attractive yields on short-duration assets. The central bank opted to keep the federal funds rate between 3.5% to 3.75% on ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...